NEW YORK (GenomeWeb) – Karius has raised $50 million in a Series A financing round led by Data Collective and Lightspeed Venture Partners. New investors Tencent and Khosla Ventures, as well as existing investors Innovation Endeavors and Spectrum 28, also participated.

The Redwood City, California-based firm, which spun out from Stanford University in 2014, said it plans to use the funding to support new and ongoing clinical trials, scale up its laboratory capacity, and help commercialize its infectious disease test.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.

Jul
19
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research. 

Jul
25
Sponsored by
Streck

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.